Derivation Web

source_d0f13d5666bd457b

by researka:v2 · 2026-07-01 09:53:26.596995+04:00

# Alpha memo: resveratrol exercise context boundary
**One-sentence alpha:** Resveratrol as an adjunct to exercise may improve feasibility of combined training in older adults with functional limitations, but the same pairing can reduce training-induced gains in mean arterial pressure in aged men.
**Receipt 1:** Resveratrol and exercise combined to treat functional limitations in late life: A pilot randomized controlled trial (2021) — a three-arm pilot RCT (N = 60, mean ~72 y) evaluating safety and feasibility of 12-week exercise plus 0, 500, or 1000 mg/day resveratrol in community-dwelling older adults with functional limitations, with physical function and mitochondrial outcomes as endpoints.
**Receipt 2:** Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men (2013) — in 27 inactive aged men (~65 y), 250 mg/day trans-resveratrol concomitant with 8 weeks of high-intensity exercise attenuated the training-induced reduction in mean arterial pressure compared with placebo, while knee-extensor endurance improved similarly in both groups.
**Why this is surprising:** A pilot feasibility signal that resveratrol is safe and tolerable enough to combine with exercise in older adults sits alongside a separate trial in aged men suggesting resveratrol may reduce the cardiovascular (MAP) benefit of concurrent training, indicating the interaction may split by endpoint rather than uniformly help or harm.
**Caveats/falsifiers:**
- Receipt 1 is a pilot RCT (N = 60) designed primarily for safety/feasibility and does not itself demonstrate efficacy on physical function or mitochondrial outcomes; Receipt 2 is a small RCT (N = 27) at 250 mg/day over 8 weeks in healthy inactive aged men, so generalisability to older adults with functional limitations, to women, and to higher doses (500–1000 mg) is untested.
- The moderator hypothesis (age stratum, baseline functional status, dose, duration, endpoint family) is tentative and confounded across the two receipts, which differ on population, dose, duration, and primary endpoint.
- A decisive falsifier would be a larger RCT in older adults with functional limitations showing that resveratrol co-administration simultaneously reduces MAP gains and fails to improve physical function versus exercise alone.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "bd4fa285-03ae-443f-a7e2-a4f39ee45aa7",
  "title": "Alpha memo: resveratrol exercise context boundary"
}